[1] |
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
|
[2] |
Chinese College of Transplant Doctors, Liver Transplantation Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese clinical practice guidelines on liver transplantation for hepatocellular carcinoma(2021 edition)[J]. Chin J Dig Surg, 2022, 21( 4): 433- 443. DOI: 10.3760/cma.j.cn115610-20220316-00135.
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J]. 中华消化外科杂志, 2022, 21( 4): 433- 443. DOI: 10.3760/cma.j.cn115610-20220316-00135.
|
[3] |
WU ZT, PENG Q, GAO Y, et al. Advances in bioartificial liver system[J]. Chin J Cell Biol, 2019, 41( 4): 594- 600. DOI: 10.11844/cjcb.2019.04.0006.
武之涛, 彭青, 高毅, 等. 生物人工肝的研究进展[J]. 中国细胞生物学学报, 2019, 41( 4): 594- 600. DOI: 10.11844/cjcb.2019.04.0006.
|
[4] |
ZHOU L, CHEN Y. Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure[J]. Chin J Hepatol, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008.
周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准[J]. 中华肝脏病杂志, 2022, 30( 2): 127- 130. DOI: 10.3760/cma.j.cn501113-20220108-00008.
|
[5] |
Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
|
[6] |
LI G, ZHANG P, ZHU Y. Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature[J]. J Viral Hepat, 2023, 30( 2): 90- 100. DOI: 10.1111/jvh.13767.
|
[7] |
WANG L, XU WX, ZHU S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: A prospective study[J]. J Clin Transl Hepatol, 2023, 11( 4): 908- 917. DOI: 10.14218/JCTH.2022.00254.
|
[8] |
XU W, ZHU S, YANG L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure[J]. J Med Virol, 2023, 95( 3): e28650. DOI: 10.1002/jmv.28650.
|
[9] |
SWAROOP S, ARORA U, BISWAS S, et al. Therapeutic plasma-exchange improves short-term, but not long-term, outcomes in patients with acute-on-chronic liver failure: A propensity score-matched analysis[J]. J Clin Apher, 2023, 38( 4): 376- 389. DOI: 10.1002/jca.22033.
|
[10] |
CHEN YY, LI H, XU BY, et al. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure: A multicenter prospective cohort study[J]. Front Med(Lausanne), 2021, 8: 779744. DOI: 10.3389/fmed.2021.779744.
|
[11] |
WU HH, LUO CL. Short-term efficacy analysis of artificial liver therapy in patients with hepatitis B virus-related acute-on-chronic liver failure with different models for end-stage liver disease score[J]. China Pract Med, 2023, 18( 13): 7- 11. DOI: 10.14163/j.cnki.11-5547/r.2023.13.002.
吴慧慧, 罗长柳. 人工肝治疗不同终末期肝病模型评分的乙型肝炎病毒相关性慢加急性肝衰竭患者的短期疗效分析[J]. 中国实用医药, 2023, 18( 13): 7- 11. DOI: 10.14163/j.cnki.11-5547/r.2023.13.002.
|
[12] |
CHEN Y. Highlight of a new clinical classification of acute-on-chronic liver failure[J]. J Pract Hepatol, 2020, 23( 4): 457- 458. DOI: 10.3969/j.issn.1672-5069.2020.04.001.
陈煜. 再论慢加急性肝衰竭新的临床分型及临床意义[J]. 实用肝脏病杂志, 2020, 23( 4): 457- 458. DOI: 10.3969/j.issn.1672-5069.2020.04.001.
|
[13] |
LIN JH, CHEN LX, LAN LQ, et al. Association between the initial time of artificial liver plasma dialysis filtration intervention and the in-hospital prognosis in patients with hepatitis B-related chronic onset acute liver failure[J]. Chin J Blood Purif, 2023, 22( 3): 221- 226. DOI: 10.3969/j.issn.1671-4091.2023.03.014.
林建辉, 陈丽霞, 蓝丽琴, 等. 人工肝血浆透析滤过干预启动时间与乙型肝炎相关性慢加急性肝衰竭患者院内预后之间的关联[J]. 中国血液净化, 2023, 22( 3): 221- 226. DOI: 10.3969/j.issn.1671-4091.2023.03.014.
|
[14] |
AN XY, HU LX, LI M, et al. A study on treatment timing selection and short-term efficacy prediction with changes in cytokine levels before and after non-biological artificial liver treatment in acute-on-chronic liver failure[J]. Chin J Hepatol, 2022, 30( 11): 1218- 1224. DOI: 10.3760/cma.j.cn501113-20220524-00278.
安薪宇, 胡灵溪, 李妹, 等. 非生物型人工肝治疗前后细胞因子水平变化对慢加急性肝衰竭治疗时机选择及其短期疗效的预测[J]. 中华肝脏病杂志, 2022, 30( 11): 1218- 1224. DOI: 10.3760/cma.j.cn501113-20220524-00278.
|
[15] |
MAIWALL R, BAJPAI M, CHOUDHURY AK, et al. Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensity-score matched study from AARC[J]. Liver Int, 2021, 41( 5): 1083- 1096. DOI: 10.1111/liv.14806.
|
[16] |
OCSKAY K, KANJO A, GEDE N, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: A systematic review and network meta-analysis[J]. Ann Intensive Care, 2021, 11( 1): 10. DOI: 10.1186/s13613-020-00795-0.
|
[17] |
LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64( 1): 69- 78. DOI: 10.1016/j.jhep.2015.08.018.
|
[18] |
YANG ZY, ZHANG ZW, CHENG QY, et al. Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients[J]. Hepatol Int, 2020, 14( 4): 491- 502. DOI: 10.1007/s12072-020-10053-x.
|
[19] |
LI S, CHEN Y. Coping with shortage of plasma-The new therapeutic pattern of non-bioartificial liver[J]. J Clin Hepatol, 2017, 33( 9): 1687- 1692. DOI: 10.3969/j.issn.1001-5256.2017.09.012.
李爽, 陈煜. 血浆紧缺情况下非生物型人工肝治疗新模式的探讨[J]. 临床肝胆病杂志, 2017, 33( 9): 1687- 1692. DOI: 10.3969/j.issn.1001-5256. 2017.09.012.
|
[20] |
LI S, ZHOU L, LIU J, et al. Clinical observation of plasma exchange replacement of partial plasma with hydroxyethyl starch in the treatment of patients with liver failure[J]. Chin J Gastroenterol Hepatol, 2019, 28( 7): 735- 739. DOI: 10.3969/j.issn.1006-5709.2019.07.004.
李爽, 周莉, 刘静, 等. 血浆置换应用羟乙基淀粉替代部分血浆治疗肝衰竭的临床观察[J]. 胃肠病学和肝病学杂志, 2019, 28( 7): 735- 739. DOI: 10.3969/j.issn.1006-5709.2019.07.004.
|
[21] |
FUJIWARA K, ABE R, YASUI S, et al. High recovery rate of consciousness by high-volume filtrate hemodiafiltration for fulminant hepatitis[J]. Hepatol Res, 2019, 49( 2): 224- 231. DOI: 10.1111/hepr.13255.
|
[22] |
TAKIKAWA Y, KAKISAKA K, SUZUKI Y, et al. Multicenter study on the consciousness-regaining effect of a newly developed artificial liver support system in acute liver failure: An on-line continuous hemodiafiltration system[J]. Hepatol Res, 2021, 51( 2): 216- 226. DOI: 10.1111/hepr.13557.
|
[23] |
KOMURA T, TANIGUCHI T, SAKAI Y, et al. Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure[J]. J Gastroenterol Hepatol, 2014, 29( 4): 782- 786. DOI: 10.1111/jgh.12440.
|
[24] |
YANG XS, ZHOU L, LI L, et al. Influence of duration of plasma diafiltration on therapeutic outcome of liver failure[J]. J Clin Hepatol, 2018, 34( 5): 1052- 1054. DOI: 10.3969/j.issn.1001-5256.2018.05.025.
杨仙珊, 周莉, 李璐, 等. 血浆透析滤过治疗时间对肝衰竭治疗效果的影响[J]. 临床肝胆病杂志, 2018, 34( 5): 1052- 1054. DOI: 10.3969/j.issn.1001-5256.2018.05.025.
|
[25] |
WAN YM, LI YH, XU ZY, et al. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: A prospective study[J]. J Clin Apher, 2017, 32( 6): 453- 461. DOI: 10.1002/jca.21535.
|
[26] |
YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34( 4): 392- 398. DOI: 10.1002/jca.21690.
|
[27] |
WU B, DU LY, MA YJ, et al. Effects of different combinations of artificial liver support system on efficacy and inflammatory indexes of patients with hepatitis B virus-related acute-on-chronic liver failure in early and middle stages[J/CD]. Chin J Liver Dis(Electronic Version), 2021, 13( 1): 32- 38. DOI: 10.3969/j.issn.1674-7380.2021.01.006.
吴蓓, 杜凌遥, 马元吉, 等. 不同组合人工肝支持系统治疗乙型肝炎病毒相关早、中期慢加急性肝衰竭患者的疗效及对炎症指标的影响[J/CD]. 中国肝脏病杂志(电子版), 2021, 13( 1): 32- 38. DOI: 10.3969/j.issn.1674-7380.2021.01.006.
|
[28] |
SALIBA F, BAÑARES R, LARSEN FS, et al. Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts[J]. Intensive Care Med, 2022, 48( 10): 1352- 1367. DOI: 10.1007/s00134-022-06802-1.
|
[29] |
MONET C, DE JONG A, AARAB Y, et al. Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center[J]. Crit Care, 2022, 26( 1): 282. DOI: 10.1186/s13054-022-04165-z.
|
[30] |
AGARWAL B, CAÑIZARES RB, SALIBA F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure[J]. J Hepatol, 2023, 79( 1): 79- 92. DOI: 10.1016/j.jhep.2023.03.013.
|
[31] |
POPESCU M, DAVID C, MARCU A, et al. Artificial liver support with CytoSorb and MARS in liver failure: A retrospective propensity matched analysis[J]. J Clin Med, 2023, 12( 6): 2258. DOI: 10.3390/jcm12062258.
|
[32] |
MA YJ, CHEN F, XU Y, et al. Safety and efficacy of regional citrate anticoagulation during plasma adsorption plus plasma exchange therapy for patients with acute-on-chronic liver failure: A pilot study[J]. Blood Purif, 2019, 48( 3): 223- 232. DOI: 10.1159/000500408.
|
[33] |
WANG M, MA YJ, DU LY, et al. Association between longer duration of citrate accumulation and 90-day mortality of acute-on-chronic liver failure[J]. Crit Care, 2021, 25( 1): 387. DOI: 10.1186/s13054-021-03819-8.
|
[34] |
PENG B, LU JQ, GUO HB, et al. Regional citrate anticoagulation for replacement therapy in patients with liver failure: A systematic review and meta-analysis[J]. Front Nutr, 2023, 10: 1031796. DOI: 10.3389/fnut.2023.1031796.
|
[35] |
WANG XY, ZHOU L, DONG JL, et al. Anticoagulant efficacy and safety comparison of nafmostat mesylate and heparin during double plasma molecular absorption system treatment in patients with liver failure[J]. J Pract Hepatol, 2023, 26( 6): 843- 846. DOI: 10.3969/j.issn.1672-5069.2023.06.019.
王新月, 周莉, 董金玲, 等. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究[J]. 实用肝脏病杂志, 2023, 26( 6): 843- 846. DOI: 10.3969/j.issn.1672-5069.2023.06.019.
|
[36] |
ZHANG K, ZHANG L, LIU W, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity[J]. Cell Stem Cell, 2018, 23( 6): 806- 819. DOI: 10.1016/j.stem.2018.10.018.
|
[37] |
WANG J, REN H, LIU Y, et al. Bioinspired artificial liver system with hiPSC-derived hepatocytes for acute liver failure treatment[J]. Adv Healthc Mater, 2021, 10( 23): e2101580. DOI: 10.1002/adhm.202101580.
|
[38] |
TUERXUN K, HE J, IBRAHIM I, et al. Bioartificial livers: a review of their design and manufacture[J]. Biofabrication, 2022, 14( 3): 1- 24. DOI: 10.1088/1758-5090/ac6e86.
|
[39] |
DUAN Z, XIN S, ZHANG J, et al. Comparison of extracorporeal cellular therapy(ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure[J]. Hepat Med, 2018, 10: 139- 152. DOI: 10.2147/HMER.S180246.
|
[40] |
THOMPSON J, JONES N, AL-KHAFAJI A, et al. Extracorporeal cellular therapy(ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial[J]. Liver Transpl, 2018, 24( 3): 380- 393. DOI: 10.1002/lt.24986.
|
[41] |
LI WJ, ZHU XJ, YUAN TJ, et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs[J]. Sci Transl Med, 2020, 12( 551): eaba5146. DOI: 10.1126/scitranslmed.aba5146.
|
[42] |
SHI XL, GAO YM, YAN YP, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes[J]. Cell Res, 2016, 26( 2): 206- 216. DOI: 10.1038/cr.2016.6.
|
[43] |
WANG Y, ZHENG Q, SUN Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30( 5): 617- 631. DOI: 10.1016/j.stem.2023.03.013.
|
[1] | Ying LIN, Li CHEN, Fei PENG, Jianhui LIN, Chuanshang ZHUO. Changes in hemoglobin and related influencing factors in patients with liver failure undergoing artificial liver support therapy[J]. Journal of Clinical Hepatology, 2025, 41(1): 104-109. doi: 10.12449/JCH250116 |
[2] | Xuejing ZHU, Weijian HUANG, Hexin YAN. Source and application of seed cells in bioartificial liver support system[J]. Journal of Clinical Hepatology, 2024, 40(2): 246-251. doi: 10.12449/JCH240205 |
[3] | Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2024 version)[J]. Journal of Clinical Hepatology, 2024, 40(12): 2371-2387. doi: 10.12449/JCH241206 |
[4] | Shoujuan LI, Li WANG, Ming ZHOU, Bei WU, Lei WANG, Meng DUAN, Hongfan LIAO, Ruiqing HU, Zhaoxia HU, Li ZHU, Juan HU. Efficacy and safety of artificial liver support therapy with a selective plasma separator in low-platelet count patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(6): 1191-1195. doi: 10.12449/JCH240619 |
[5] | Shuang SUN, Jinquan LIU, Shuai FENG, Shuxian WANG, Xiangmei XU, Deshu DAI, Jianhong WANG, Jinzhen CAI, Chuanshen XU. Successful trans-blood liver transplantation after artificial liver support therapy in a patient with hepatic coma: A case report[J]. Journal of Clinical Hepatology, 2024, 40(4): 791-793. doi: 10.12449/JCH240423 |
[6] | Jing ZHANG, Xinmin ZHOU. Artificial liver support therapy for patients with pre-liver failure[J]. Journal of Clinical Hepatology, 2024, 40(2): 229-232. doi: 10.12449/JCH240202 |
[7] | Tao HAN, Qian ZHANG. Clinical practice and research advances in artificial liver support therapy[J]. Journal of Clinical Hepatology, 2024, 40(2): 225-228. doi: 10.12449/JCH240201 |
[8] | Yuhang CHEN, Zimeng JIANG, Zhijiao ZHANG, Mengyao ZHENG, Meilian WANG, Hua HUANG, Gongfang ZHAO. The influence of diagnostic criteria of different guidelines on short-term prognosis of artificial liver therapy for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(11): 2629-2634. doi: 10.3969/j.issn.1001-5256.2023.11.017 |
[9] | Yuanji MA, Lingyao DU, Lang BAI, Hong TANG. Anticoagulants for artificial liver support therapy: Application advances and selection strategies[J]. Journal of Clinical Hepatology, 2022, 38(10): 2396-2401. doi: 10.3969/j.issn.1001-5256.2022.10.038 |
[10] | Li Shuang, Liu Jing, Chen Yu. Non-bioartificial liver in liver failure: Clinical application and research advances[J]. Journal of Clinical Hepatology, 2019, 35(9): 1909-1915. doi: 10.3969/j.issn.1001-5256.2019.09.004 |
[11] | Chen Hao, Ma JunYong, Qian LiQiang, Yin GuoWen. Value of spleen stiffness and spleen volume in predicting posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(12): 2725-2729. doi: 10.3969/j.issn.1001-5256.2019.12.017 |
[12] | Zhu Bing, Xin ShaoJie, You ShaoLi. Precision medicine and treatment strategies for liver failure[J]. Journal of Clinical Hepatology, 2018, 34(9): 1832-1835. doi: 10.3969/j.issn.1001-5256.2018.09.003 |
[13] | Wang GuangYi, Shi XiaoJu, Jiang Chao, Sun XiaoDong, Qiu Wei, Lu: GuoYue. One case of liver transplantation for liver failure due to adult- onset Still's disease[J]. Journal of Clinical Hepatology, 2014, 30(1): 67-68. doi: 10.3969/j.issn.1001-5256.2014.01.018 |
[14] | Wang Xian, Wang ShaoYang, Huang DeDong, Chen Jian, Chen DeLiang. Analysis of short-term prognostic factors in patients with HBV-related acute-on-chronic liver failure treated with artificial liver support system[J]. Journal of Clinical Hepatology, 2014, 30(4): 367-369. doi: 10.3969/j.issn.1001-5256.2014.04.020 |
[15] | Zhang AiMin, Xin ShaoJie. Virus infection and liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 729-731. |
[16] | Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52. |
[17] | Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98. |
[18] | Li ShuangXing, Shi LiJun, Wang XiuJie. Effects of bone marrow mesenchymal stem cells transplantation into rats with acute liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 624-626. |
[19] | Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623. |